Literature DB >> 10147041

Pharmaceutical formulation and healthcare expenditures.

D A Sclar, T L Skaer.   

Abstract

Mesh：

Year:  1992        PMID： 10147041     DOI： 10.2165/00019053-199202040-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  16 in total

1.  Drugs as a reason for nursing home admissions.

Authors:  L R Strandberg
Journal:  J Am Health Care Assoc       Date:  1984-07

Review 2.  New drug legislation: a response from the pharmaceutical industry.

Authors:  P E Freiman
Journal:  Health Aff (Millwood)       Date:  1990       Impact factor: 6.301

3.  Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals.

Authors:  D Henry
Journal:  Pharmacoeconomics       Date:  1992-01       Impact factor: 4.981

Review 4.  Trends in retail prescription expenditures.

Authors:  S W Schondelmeyer; J Thomas
Journal:  Health Aff (Millwood)       Date:  1990       Impact factor: 6.301

Review 5.  The elderly and drug policy: coming of age.

Authors:  J Avorn
Journal:  Health Aff (Millwood)       Date:  1990       Impact factor: 6.301

6.  Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies.

Authors:  A L Hillman; J M Eisenberg; M V Pauly; B S Bloom; H Glick; B Kinosian; J S Schwartz
Journal:  N Engl J Med       Date:  1991-05-09       Impact factor: 91.245

7.  Utility of a transdermal delivery system for antihypertensive therapy. Part 2.

Authors:  D A Sclar; T L Skaer; A Chin; M P Okamoto; M A Gill
Journal:  Am J Med       Date:  1991-07-18       Impact factor: 4.965

8.  How often is medication taken as prescribed? A novel assessment technique.

Authors:  J A Cramer; R H Mattson; M L Prevey; R D Scheyer; V L Ouellette
Journal:  JAMA       Date:  1989-06-09       Impact factor: 56.272

9.  The social drug lag: an examination of pharmaceutical approval delays in Medicaid formularies.

Authors:  S O Schweitzer; H Salehi; N Boling
Journal:  Soc Sci Med       Date:  1985       Impact factor: 4.634

10.  Improved compliance measures: applications in an ambulatory hypertensive drug trial.

Authors:  P Rudd; S Ahmed; V Zachary; C Barton; D Bonduelle
Journal:  Clin Pharmacol Ther       Date:  1990-12       Impact factor: 6.875
View more
  4 in total

Review 1.  Noncompliance with antihypertensive therapy. Economic consequences.

Authors:  T L Skaer; D A Sclar; L M Robison
Journal:  Pharmacoeconomics       Date:  1996-01       Impact factor: 4.981

2.  Drug expenditures in a balanced strategy for healthcare policy.

Authors:  R J Bonk; M J Myers; W F McGhan
Journal:  Pharmacoeconomics       Date:  1995-06       Impact factor: 4.981

3.  Translating safety, efficacy and compliance into economic value for controlled release dosage forms.

Authors:  M P Cramer; S R Saks
Journal:  Pharmacoeconomics       Date:  1994-06       Impact factor: 4.981

4.  Compliance and hypertension.

Authors:  F B Garfield; J J Caro
Journal:  Curr Hypertens Rep       Date:  1999-12       Impact factor: 5.369
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.